150 related articles for article (PubMed ID: 26802151)
21. [The clinical features, survival analysis, and geriatric assessment of 85 patients with follicular lymphoma: a single-center study].
Yin JJ; Qian L; Bai JF; Feng R; Li JT; Wang T; Zhang CL; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):233-241. PubMed ID: 38716594
[No Abstract] [Full Text] [Related]
22. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
Pedersen MA; Gormsen LC; Jakobsen LH; Eyre TA; Severinsen MT; Baech J; Dann EJ; Knapp A; Sahin D; Vestergaard P; El-Galaly TC; Jensen P
Br J Haematol; 2024 Apr; 204(4):1271-1278. PubMed ID: 37957542
[TBL] [Abstract][Full Text] [Related]
23. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
[TBL] [Abstract][Full Text] [Related]
24. Transformed lymphoma: what should I do now?
Smith S
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):306-311. PubMed ID: 33275671
[TBL] [Abstract][Full Text] [Related]
25. Follicular lymphoma in the United States: first report of the national LymphoCare study.
Friedberg JW; Taylor MD; Cerhan JR; Flowers CR; Dillon H; Farber CM; Rogers ES; Hainsworth JD; Wong EK; Vose JM; Zelenetz AD; Link BK
J Clin Oncol; 2009 Mar; 27(8):1202-8. PubMed ID: 19204203
[TBL] [Abstract][Full Text] [Related]
26. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Strefford JC; Nowicka M; Hargreaves CE; Burton C; Davies A; Ganderton R; Hiddemann W; Iriyama C; Klapper W; Latham KV; Martelli M; Mir F; Parker H; Potter KN; Rose-Zerilli MJJ; Sehn LH; Trněný M; Vitolo U; Bolen CR; Klein C; Knapp A; Oestergaard MZ; Cragg MS
Blood Adv; 2021 Aug; 5(15):2935-2944. PubMed ID: 34323957
[TBL] [Abstract][Full Text] [Related]
27. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract][Full Text] [Related]
28. Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
Smith MR; Jegede O; Martin P; Till B; Parekh S; Yang DT; Hsi ED; Witzig TE; Dave SS; Scott DW; Hanson CA; Kostakoglu L; Abdel Samad NN; Casulo C; Bartlett NL; Caimi PF; Al Baghdadi T; Blum K; Romer M; Inwards DJ; Lerner R; Wagner L; Little RF; Friedberg JW; Leonard JP; Kahl BS
Blood; 2024 May; ():. PubMed ID: 38820500
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
Tobin JWD; Rule G; Colvin K; Calvente L; Hodgson D; Bell S; Dunduru C; Gallo J; Tsang ES; Tan X; Wong J; Pearce J; Campbell R; Tneh S; Shorten S; Ng M; Cochrane T; Tam CS; Abro E; Hawkes E; Hodges G; Kansara R; Talaulikar D; Gilbertson M; Johnston AM; Savage KJ; Villa D; Morris K; Ratnasingam S; Janowski W; Kridel R; Cheah CY; MacManus M; Matigian N; Mollee P; Gandhi MK; Hapgood G
Blood Adv; 2019 Oct; 3(19):2804-2811. PubMed ID: 31570492
[TBL] [Abstract][Full Text] [Related]
30. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.
Zhao J; Xu Z; Liu D; Lu Q
Cancer Cell Int; 2012 Aug; 12(1):38. PubMed ID: 22913602
[TBL] [Abstract][Full Text] [Related]
31. Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
Chu Y; Liu Y; Yu Z; Zhan L; Lu T; Jiang Y; Fang X; Zhou X; Wang X
Cancer; 2024 Apr; 130(7):1072-1082. PubMed ID: 38041532
[TBL] [Abstract][Full Text] [Related]
32. Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.
Rajamaki A; Sorigue M; Prusila REI; Kuusisto MEL; Kuitunen H; Jantunen E; Mercadal S; Turpeenniemi-Hujanen T; Sancho JM; Sunela K; Kuittinen O
Acta Oncol; 2024 May; 63():267-272. PubMed ID: 38709114
[TBL] [Abstract][Full Text] [Related]
33. Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) FL with CAR-T Cell Therapy: A Vodcast and Case Example.
Hübel K
Oncol Ther; 2024 Mar; ():. PubMed ID: 38512599
[TBL] [Abstract][Full Text] [Related]
34. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim SH; Vaca R; Wei C; Rector D; Sundaram S; Reddy N; Lin Y; Farooq U; D'Angelo C; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Yazdy M; Rabinovich E; Varma G; Karmali R; Mian A; Savani M; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein AK; Blum KA; Boughan KM; Smith SE; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Ramdial J; Maliske SM; Epperla N; Venugopal P; Feldman TA; Smith SD; Stadnik A; David KA; Naik S; Lossos IS; Lunning MA; Caimi P; Kamdar M; Palmisiano N; Bachanova V; Portell CA; Phillips T; Olszewski AJ; Alderuccio JP
Blood; 2021 Jan; 137(3):374-386. PubMed ID: 32663292
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
Kahl BS; Jegede OA; Peterson C; Swinnen LJ; Habermann TM; Schuster SJ; Weiss M; Fishkin PA; Fenske TS; Williams ME
J Clin Oncol; 2024 Mar; 42(7):774-778. PubMed ID: 38194625
[No Abstract] [Full Text] [Related]
36. Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.
Leich E; Brodtkorb M; Schmidt T; Altenbuchinger M; Lingjærde OC; Lockmer S; Holte H; Nedeva T; Grieb T; Sander B; Sundström C; Spang R; Kimby E; Rosenwald A
Leuk Lymphoma; 2023 Dec; 64(12):1927-1937. PubMed ID: 37683053
[TBL] [Abstract][Full Text] [Related]
37. Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China.
Gao F; Zhang T; Liu X; Qu Z; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Wang X; Zhang H
Front Oncol; 2022; 12():863021. PubMed ID: 36185179
[TBL] [Abstract][Full Text] [Related]
38. Digital and manual interfollicular Ki-67 are associated with a progression-free survival in patients with low-grade follicular lymphoma.
Nasir A; Hegerova L; Yousaf H; Forster CL; Shanley R; Linden MA; Bachanova V; Yohe S
Am J Clin Pathol; 2024 Apr; 161(4):380-387. PubMed ID: 38044670
[TBL] [Abstract][Full Text] [Related]
39. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
Epperla N; Zhao Q; Karmali R; Torka P; Shea L; Oh TS; Anampa-Guzmán A; Reves H; Tavakkoli M; Greenwell IB; Hansinger E; Umyarova E; Annunzio K; Sawalha Y; Christian B; Thomas C; Barta SK; Geethakumari PR; Bartlett NL; Grover NS; Olszewski AJ
Blood Adv; 2023 Sep; 7(17):5038-5046. PubMed ID: 37315169
[TBL] [Abstract][Full Text] [Related]
40. The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.
Galimberti S; Ciabatti E; Ercolano G; Grassi S; Guerrini F; Cecconi N; Rousseau M; Cervetti G; Mazziotta F; Iovino L; Falzetti F; Falcinelli F; Bosi A; Rigacci L; Kovalchuk S; Vallisa D; Macchia L; Ciancia E; Petrini M
Front Pharmacol; 2017; 8():413. PubMed ID: 28706485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
